Written by Kristina Campbell – This article originally appeared in the online publication The Microbiome Times Many individuals living with chronic disease—whether it’s asthma, allergies, atopic dermatitis, type 2 diabetes, or another condition—readily confirm their therapeutic options leave a lot to be desired. Even if an existing drug product deals adequately with their symptoms, it often […]
“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute (PRI), are working in collaboration within the ‘Intestinal Microbiome-based Medicines European Task Group (IMM-ETG)’ to propose a harmonised, pan-European, regulatory approach to intestinal microbiome whole ecosystem[1]-based therapeutics” Monday, 20 May 2019 – Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma […]
The following web article is an update on the status of the PRI’s operations and initiatives for the current fiscal year (October 2018 – September 2019). This information was previously communicated to the PRI Members in a dedicated e-mail. Dear members, partners and friends of the Pharmabiotic Research Institute (PRI), 2019 has already been […]
PRI whereabouts – Spring 2018 Following our successful travels in late 2017 and early 2018 Magali Cordaillat-Simmons and myself will be out and about again throughout the spring attending a variety of conferences related to the world of Microbiotic Medicinal Products. Please feel free to get in touch with us to set up a meeting […]
